Patents Assigned to LTS Lohmann Therapie-Systeme AG
  • Publication number: 20210287764
    Abstract: A device and a method for determining a suitability of an active ingredient to be applied transdermally or transmucosally. In particular, a system that includes: at least one input device for inputting at least one designation of an active ingredient; a database for storing a plurality of data at least relating to the active ingredient; a computing unit for assessing a suitability of the active ingredient to be applied transdermally and/or transmucosally while taking into consideration data entered via the input device and/or data stored in the database; and an output device for displaying the assessed suitability.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 16, 2021
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Hanshermann Franke, Patrick Mohr, René Eifler, Marius Bauer
  • Patent number: 11083734
    Abstract: The present invention relates to an oral film consisting essentially of dexamethasone and hydroxypropyl methylcellulose, wherein the concentration of dexamethasone is 30% w/w or more and the concentration of hydroxypropyl methylcellulose is between 35 and 70% w/w based on total dry matter.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 10, 2021
    Assignees: ACUCORT AB, LTS LOHMANN THERAPIE-SYSTEME AG
    Inventor: Bengt Arvid Westrin
  • Patent number: 11045387
    Abstract: A single-dose package for transdermal therapeutic systems or film-shaped administration forms, in the form of a tear-open sealed-edge pouch with a completely surrounding and continuous non-peelable sealing surface. The single-dose packages are provided with two packaging material elements, which are arranged one lying on top of the other and form the upper side and underside of a pouch that contains the product. At least one packaging material element is a tear-resistant film laminate with an at least three-layer structure, wherein at least one layer of the packaging material elements is a metal layer. The single-dose package also has a linear weakening, which lies in the sealing area, does not touch the edge of the package and extends in the direction of the weaker tear resistance of the upper side and underside and the linear form of the anisotropically tear-resistant plastic.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: June 29, 2021
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventor: Markus Krumme
  • Patent number: 11033512
    Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising an asenapine-containing layer structure, said asenapine-containing layer structure comprising A) a backing layer and B) an asenapine-containing layer, wherein the transdermal therapeutic system comprises a silicone acrylic hybrid polymer.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 15, 2021
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Patrick Mohr, René Rietscher, René Eifler, Olga Bourquain
  • Patent number: 11033723
    Abstract: Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: June 15, 2021
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Wolfgang Laux, Beatrix Platt, Nico Reum
  • Publication number: 20210130077
    Abstract: A device for dispensing active ingredient-containing or active ingredient-carrying strips, including a housing in which a coil chamber for receiving an active ingredient-containing or active ingredient-carrying band is arranged, in which a gear transmission with a driven roller for conveying the band is mounted, and in which a separating device for separating the strips from the band is arranged. A method for dispensing active ingredient-containing or active ingredient carrying strips using such a device is also disclosed. An active ingredient-containing or active ingredient-carrying band is arranged between the driven roller and the pressure roller. A shift clutch transmission having a manually actuatable trigger element is arranged upstream of the gear transmission. The driven roller can be driven in incremental strips by the shift clutch transmission. A device and method is disclosed for dispensing active ingredient-containing or active ingredient-carrying strips with a largely equal dosage are developed.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Applicant: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: MARC BLOMENKEMPER, MICHAEL LINN, RONALD HACKBARTH, MARKUS BEE
  • Patent number: 10980753
    Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: April 20, 2021
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Patrick Mohr, René Rietscher, René Eifler, Olga Bourquain
  • Patent number: 10940122
    Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 9, 2021
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Walter Müller, Thomas Hille
  • Patent number: 10898449
    Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: January 26, 2021
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Patrick Mohr, René Rietscher, René Eifler, Olga Bourquain
  • Patent number: 10888658
    Abstract: A disposable injector with a piston actuation ram is mounted in a housing, is loaded by a spring energy accumulator and can be unlocked by a displaceable trigger device. The piston actuation ram can be supported by a tensioning rod mounted in the housing. The trigger device comprises a trigger ring displaceable relative to the housing. The tensioning rod can be supported directly or indirectly by a bearing surface of the trigger ring. The bearing surface encloses an angle of between ten degrees and forty five degrees with the longitudinal direction of the disposable injector. The point of the angle lies offset with respect to the trigger ring in the triggering direction of the disposable injector. A disposable injector with increased trigger reliability is developed.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: January 12, 2021
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Sara Forghani, Uwe Wortmann, Karsten Heuser, Heiko Spilgies
  • Patent number: 10881607
    Abstract: The invention relates to a composition for transdermal delivery, particularly iontophoretic transdermal delivery, of at least one cationic active agent or a salt thereof. The composition includes at least one cationic active agent or a salt thereof, at least one polyamine or/and polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. The invention further relates to the use of such composition as a component of a transdermal patch or of an iontophoretic transdermal patch, as well as to the use of such composition in a method for transdermally and/or iontophoretically administering cationic active agents. The invention further includes methods for determining the in vitro skin permeation properties of an active-agent-containing iontophoretic composition.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 5, 2021
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Christoph Schmitz, Mohammad Sameti, Andreas Koch, Michael Horstmann
  • Patent number: 10881606
    Abstract: A composition for transdermal delivery, particularly iontophoretic transdermal delivery, having at least one cationic active agent or a salt thereof. The composition comprises at least one cationic active agent or a salt thereof, at least one polyamine and/or polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. Use of the composition as a component of a transdermal patch or of an iontophoretic transdermal patch is also provided, as well as the use of the composition in a method for transdermally or iontophoretically administering cationic active agents. A method for determining the in vitro skin permeation properties of an active agent-containing iontophoretic composition is also provided.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: January 5, 2021
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Christoph Schmitz, Mohammad Sameti, Andreas Koch, Michael Horstmann
  • Publication number: 20200330434
    Abstract: The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound that includes: a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, one or more dicarboxylic acids, 0.5 to 10.0 wt.-% (based on the total weight of the composition) of one or more monocarboxylic acids, and water or an aqueous solvent mixture. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.
    Type: Application
    Filed: December 13, 2018
    Publication date: October 22, 2020
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael LINN, Christoph SCHMITZ, Hanshermann FRANKE
  • Publication number: 20200323787
    Abstract: The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound. The inventive compositions include a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, a dicarboxylic acid, and water or an aqueous solvent mixture, with the composition being free of monocarboxylic acids. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.
    Type: Application
    Filed: December 13, 2018
    Publication date: October 15, 2020
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael LINN, Christoph SCHMITZ, Hanshermann FRANKE
  • Publication number: 20200316055
    Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, c) a viscosity-increasing substance in an amount of about 0.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 8, 2020
    Applicant: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Thomas Hille, Gabriel Wauer, Frank Seibertz, Shu-Lun Weinheimer
  • Publication number: 20200306204
    Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) e a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact
    Type: Application
    Filed: January 31, 2020
    Publication date: October 1, 2020
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Thomas Hille, Gabriel Wauer, Kevin John Smith, Helen Elizabeth Johnson, Gillian Elizabeth Mundin
  • Patent number: 10772845
    Abstract: The invention relates to a transdermal therapeutic system (TTS) which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system incorporates a back layer and an active substance-containing layer that includes at least one peptide and a carrier substance.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: September 15, 2020
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Horst Dzekan, Sandra Wiedersberg
  • Patent number: 10744176
    Abstract: An edible orally disintegrating tablet dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible orally disintegrating tablet dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: August 18, 2020
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Li, Markus Krumme
  • Publication number: 20200253957
    Abstract: The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing matrix layer on said buprenorphine-impermeable backing layer, the matrix layer comprising a) a polymer base, b) buprenorphine, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the polymer base, and C) a skin contact layer on said buprenorphine-containing matrix layer comprising a polymer-based pressure-sensitive adhesive, and optionally wherein the buprenorphine-conta
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Applicant: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Gabriel Wauer, Thomas Hille, Kevin John Smith, Gillian Elizabeth Mundin, Helen Elizabeth Johnson
  • Publication number: 20200237748
    Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance.
    Type: Application
    Filed: April 9, 2020
    Publication date: July 30, 2020
    Applicant: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Thomas Hille, Gabriel Wauer, Frank Seibertz, Shu-Lun Weinheimer